Kymera Therapeutics, Inc. (KYMR) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to Chimera's Immunology Innovation Day, our virtual event to introduce our next immunology program, IREF5. I'm Justine Konigsberg, Chimera's Head of Investor Relations. Please note that we are hosting today's event in lieu of our regularly scheduled quarterly update call. However, we have reported our results and filed our 10Q this morning. For additional details on our Q1 results, please reference our press release issued this morning, which is available in the IR section of our website. During today's presentation, you'll hear from our team about our strategy, our pipeline advancements, and our next high-value immunology program. Joining me this morning are Nello Manolfi, our founder, president, and CEO, Jared Golub, our chief medical officer, and Veronica Campbell, our senior director of immunology and project team leader of our newly introduced program, IRAF5. Here's a snapshot of today's agenda. Nello will begin with an overview of our strategy and the opportunity with small molecule degraders. Then Jared will provide a high level overview of our STAT6 program. And we'll conclude with our prepared remarks with a discussion of our newly introduced IRA5 program before we open the call to questions. If you'd like to ask a question, please use the raise hand icon, which can be found at the bottom of your meeting window. To help us move efficiently through the Q&A discussion, we ask that you are ready to unmute your line and turn your camera on when called upon. A replay of today's event, including a copy of our corresponding presentation, will be available soon after the call concludes in the investor section of our website. But before we begin, I would like to remind you that today's presentation will include forward-looking statements abou...